Context There have been substantial changes in the management of patients with metastatic
renal cell carcinoma (mRCC) over the past decade, with upfront immunotherapy-based …

The immune checkpoint cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is an
inhibitory regulator of T-cell mediated responses that has been investigated as target of …

Background The phase 3 CheckMate 214 trial demonstrated higher response rates and
improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line …

Context Identifying the most effective first-line treatment for metastatic renal cell carcinoma
(mRCC) is challenging as rapidly evolving data quickly outdate the existing body of …

Simple Summary Kidney cancer is a frequent malignant tumor that accounts for
approximately 5% of all cancer incidences. It affects both males and females, but males are …

Several first-line immune-checkpoints inhibitors (ICI) based combinations have been studied
in metastatic renal cell carcinoma (mRCC) without any direct comparison between the …

Background Immuno-oncology (IO) agents and tyrosine kinase inhibitors (TKIs) have
revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). Data on …

N7-Methylguanosine (m7G) and long non-coding RNAs (lncRNAs) have been widely
reported to play an important role in cancer. However, there is little known about the …

Kidney disease management and treatment are currently causing a substantial global
burden. The kidneys are the most important organs in the human urinary system, selectively …

The fundamental novelty in the pathogenesis of renal cell carcinoma (RCC) was discovered
as a result of the recent identification of the role of long non-coding RNAs (lncRNAs). Here …